Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17403597 | 0.84 | CHRM2 (0.41) | CHRM2CHRM1CHRM3LTA4HTLR7 | |
| SCHEMBL15974982 | 0.79 | LTA4H (0.40) | CHRM2CHRM1CHRM3LTA4HPDCD1 | |
| SCHEMBL15974983 | 0.79 | LTA4H (0.40) | CHRM2CHRM1CHRM3LTA4HPDCD1 | |
| SCHEMBL13460128 | 0.79 | MAP4K4 (0.41) | CHRM2CHRM1CHRM3LTA4HTLR7 | |
| SCHEMBL13460106 | 0.79 | MAP4K4 (0.41) | CHRM2CHRM1CHRM3LTA4HTLR7 | |
| SCHEMBL3402167 | 0.78 | S1PR1 (0.47) | LTA4HALDH1A1PDCD1CD274S1PR1 | |
| SCHEMBL28045437 | 0.78 | ALDH1A1 (0.44) | CHRM2CHRM1CHRM3ALDH1A1PDCD1 | |
| SCHEMBL28045438 | 0.78 | ALDH1A1 (0.44) | CHRM2CHRM1CHRM3ALDH1A1PDCD1 | |
| SCHEMBL6234696 | 0.77 | MAPT (0.41) | LTA4HALDH1A1S1PR1 | |
| SCHEMBL3935123 | 0.76 | ALDH1A1 (0.57) | LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| CN-101981036-A | Pyrrolo [2, 3-D] pyridines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG | 2011-02-23 | — | — | CN | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | CHRM2 4711/4885CHRM1 4279/4885CHRM3 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.